hide message

Hello! Welcome to the Resource Centre.

We hope you find our free tools and resources useful. Did you know we also work directly with community advocates, providing them with the skills and resources to document corporate human rights abuses and effectively communicate with business?

This is only possible through generous donations from people like you.

Please consider supporting our work.

Thank you,
Phil Bloomer, Executive Director

Donate now hide message

Abbott & human rights

Abbott Laboratories and health as a human right

In April 2007, the Interfaith Center on Corporate Responsibility published a report on Abbott Laboratories and health as a human right:

'Right to Health' Creates Substantial Human Rights Risks for Abbott Laboratories, Report Finds: New report finds 'present response to access to medicines issues is inadequate' and recommends Abbott approach access to medicines as human rights obligation

Abbott Laboratories' primary human rights challenge is the right to health, a new report by the Interfaith Center on Corporate Responsibility has found... [The report] evaluates the legal and business risks facing Abbott Laboratories under current human rights law...[and] argues the company should "address the right to health through responsible company behavior, and not through philanthropy alone."

full report: "Human Rights Challenges Facing Abbott Laboratories: Risks and recommendations" [PDF]

 

In response, Abbott provided the following statement:

[PDF] Abbott's Commitment to Global HIV Care

In August 2006, the World Health Organization (WHO) identified heat-stable lopinavir/ritonavir (LPV/r) tablets as the recommended protease inhibitor for second-line therapy in resource-limited settings, because it is co-formulated and does not require refrigeration, which are key benefits for patients living in the developing world... To help ensure that all patients who need our HIV medicine can get it, Abbott has implemented five practical measures: 

  • Innovation
  • Broad Registration
  • Lower-strength Tablet for Pediatric Use
  • Building Ongoing and Quality Supply
  • Tiered and Affordable Pricing

full statement by Abbott here [PDF]

Get RSS feed of these results

Related stories and components

Company non-response
30 May 2007

Abbott Laboratories did not respond to: Interfaith Center on Corporate Responsibility report says Abbott Labs faces risks over access to medicines - recommends adopting human rights-based approach

Read more

Article
1 May 2007

[PDF] Abbott's Commitment to Global HIV Care

Author: Abbott Laboratories

In August 2006, the World Health Organization (WHO) identified heat-stable lopinavir/ritonavir (LPV/r) tablets as the recommended protease inhibitor for second-line therapy in resource-limited settings, because it is co-formulated and does not...

Read more